Back to search results
Thomas Hope
Thomas Hope

Thomas Hope, MD

Diagnostic Radiology | Neuroendocrine Oncology

Center for Neuroendocrine Tumors
1825 Fourth St.,
San Francisco, CA 94158
+3 more locations
(415) 502-2858
Virtual visits available
Virtual visits available
Center for Neuroendocrine Tumors
1825 Fourth St.,
San Francisco, CA 94158
+3 more locations
(415) 502-2858

Dr. Thomas Hope is a radiologist and nuclear medicine physician (an expert in medical applications of radioactive substances). He specializes in neuroendocrine tumors, with a focus on peptide receptor radionuclide therapy, which targets these cancer cells with a high dose of radiation. He has a special interest in molecular imaging and in treating cancer using the targeted, individualized techniques of precision medicine.

In addition to working with patients, Hope conducts research on novel radiopharmaceuticals, or new radioactive imaging substances that can help physicians locate tumors. He also works on combining different imaging modalities – such as positron emission tomography and MRI – to stage cancer in patients.

Hope received his medical degree from Stanford University School of Medicine. He completed a residency in diagnostic radiology at UCSF. He then completed a fellowship in nuclear medicine and body MRI at Stanford.

Hope is a member of the Radiological Society of North America, Society of Nuclear Medicine and Molecular Imaging, Society of Abdominal Radiology and International Society for Magnetic Resonance in Medicine.

  • Board Certifications

    American Board of Nuclear Medicine, Nuclear Medicine, 2013

    American Board of Radiology, Diagnostic Radiology, 2012

  • Fellowships

    Stanford University Medical Center-GME, Nuclear Medicine, 2013

  • Residencies

    UCSF, Radiology, General, 2012

  • Internship

    Kaiser Foundation Hospital, Internal Medicine, 2008

  • Degree

    Stanford University School of Medicine, 2007

  • Languages

    English

Conditions I specialize in

Where I see patients (4)

    Selected research

    See all research
    Decorative Caduceus

    Comparison of Whole Body DWI to FDG PET

    The overall proportion of lesions that will be characterized as positive on whole body (WB) diffusion weight imaging (DWI) and FDG PET.

    Recruiting

    Decorative Caduceus

    Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

    The proportion of patients who achieve a greater than 50% decline from baseline prostate specific antigen (PSA) (PSA50) drawn prior to C1D1, at any point in the treatment course, will be descriptively reported along with 95% binom...

    Recruiting

    Decorative Caduceus

    Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617

    The mean tumor absorbed dose on post-treatment SPECT imaging within 7 days of the first radioligand treatment (RLT) will be obtained by using MIM Software to measure absorbed dose and researchers will manually segment activity in ...

    Recruiting

    Decorative Caduceus

    Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastat...

    PSA progression is defined as a rise in PSA at > 12 weeks by more than 25% and more than 2ng/mL above the nadir (lowest PSA point).

    Recruiting

    Decorative Caduceus

    Imaging of Solid Tumors Using DLL3 SPECT

    Standardized Uptake Values (SUVs) will be calculated for up to five lesions in each patient, with mediastinal blood pool being used as background activity. The median and range will be reported across all Response Evaluation Crite...

    Recruiting

    Decorative Caduceus

    18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas

    Sensitivity of 18F-fluorocholine PET for the detection of abnormal parathyroid adenomas confirmed by pathology as compared to sestamibi imaging. Location of parathyroid adenoma at imaging as read by three blinded readers, will be ...

    Recruiting

    Decorative Caduceus

    Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer

    Reclassification rate is defined as the proportion of participants what will be characterized as metastatic on I-124 Positron Emission Tomography (PET) that are characterized as localized or nodal only disease on a non-investigati...

    Recruiting

    Decorative Caduceus

    Mechanisms of Resistance to PSMA Radioligand Therapy

    The unit density sphere model will be implemented using OLINDA, a second-generation personal computer software for internal dose assessment in nuclear medicine to measure mean dose across all metastatic lesions. This approach uses...

    Recruiting

    Decorative Caduceus

    Imaging of Solid Tumors Using FAP-2286

    The frequency and severity of treatment emergent adverse events following FAP-2286 injection will be descriptively reported as classified and graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI ...

    Recruiting

    Contact me

    Share